BioNetwork 2019

October 23 - 25, 2019

The Ritz-Carlton Laguna Niguel, CA

1.888.482.6012

2017 agenda day 1

Day 1: Monday, October 23, 2017 (Past Event)


+ Show All Session Details Day 1 Day 2 Day 3

07:30 AM - 08:30 AM Registration and Breakfast

08:30 AM - 08:35 AM Welcome Remarks

08:35 AM - 08:50 AM Chairperson’s Opening Remarks

Chris Leo, SVP, Back Bay Life Science Advisors

img

Chris Leo

SVP
Back Bay Life Science Advisors

08:50 AM - 9:35 AM Opening Guest Keynote: A Wake Up Call to Drug Companies from Your Friendly Neighborhood Payer

Kent Rogers, SVP, Industry Relations, OptumRx, UnitedHealth Group
Having spent 20 years working in Pharma, Kent Rogers knows first-hand that the industry lacks a fundamental understanding of the payer landscape -- who payers are, what they do, and most importantly, what drugmakers need to know. Now as an executive at one of the largest payers in the country, Kent can offer a unique perspective into the complex Pharma/Payer environment and what the shifting dynamics mean for drug pricing. As Senior Vice President of Industry Relations for OptumRx, a division of Optum under the United Health Group enterprise, Kent's team is responsible for over $600M in procurement of brand, generic and specialty drugs, all contracting for rebate management of $80B in annual drug spend for all books of internal and external business with United Health Group. His talk will address:

Understanding each other’s business: what Pharma needs to know about the payer business prior to commercialization, and visa versa
Engaging in a dialogue, starting with what payers need from drug companies
Timelines: when should your team start have a reimbursement plan in place? At what point are you falling behind?
Top payer trends to pay attention to in 2018 and beyond


img

Kent Rogers

SVP, Industry Relations
OptumRx, UnitedHealth Group
1. Oncology
Michael Weingarten, SBIR Development Center, National Cancer Institute

2. Immunology
Kia Motesharei, VP, Global Head of Business Development; Neurology & Immunology Global Business Development & Alliance Management; EMD Serono

3. Immuno-oncology
Prakash Raman, VP, Global Head of Oncology Business Development & Licensing, Novartis Oncology

4. Rare and Orphan Diseases
Joe Whalen, SVP, Business Development & Alliance Management; Horizon

5. Pain

6. Gene Therapy
Greg Fond, Director, External Innovation, Sanofi

7. Diabetes

8.CNS & Neurodegenerative Diseases
Murali Gopalakrishnan, Senior Director & Head Search & Evaluation Neuroscience, Abbvie

9. Infectious Diseases


img

Kia Motesharei

VP, Global Head of Business Development, Neurology & Immunology Global Busi
EMD Serono
img

Prakash Raman

VP, Global Head of Oncology Business Development & Licensing
Novartis Oncology
img

Joe Whalen

SVP, Business Development & Alliance Management
Horizon
img

Greg Fond

Director, External Innovation
Sanofi
img

Murali Gopalakrishnan

Senior Director & Head Search & Evaluation Neuroscience
Abbvie
img

Michael Weingarten

Director, SBIR Development Center
National Cancer Institute

10:35 AM - 10:50 AM Biotech Spotlights

Grace Colon, CEO, InCarda Therapeutics

img

Grace Colon

CEO
InCarda Therapeutics
  • What does the change in FDA leadership mean for pharma?
  • Changes in federal funding and the enactment of the 21st Century Cures Act
  • What to expect in terms of tax reforms
  • Current developments in the pricing debate

img

Marc Schwabish

US Head, Pharma Business Development & Licensing
Bayer
img

Sara Radcliffe

President & CEO
California Life Sciences Association
img

Scott Goedeke

President
Viscadia

1:1 Partnering

10:50 AM - 11:20 AM 1:1 Partnering

General Session

11:20 AM - 11:50 AM Morning Refreshment Break

1:1 Partnering

11:20 AM - 11:50 AM 1:1 Partnering

What is the emerging science in the space?
Where are the most interesting opportunities?
What are the transactional challenges to overcome?

img

Murali Gopalakrishnan

Senior Director & Head Search & Evaluation Neuroscience
Abbvie
img

Steven Bartz

Director, Worldwide Licensing
Merck & Co.
img

Michelle Hoffmann

Senior Vice President
Back Bay Life Science Advisors

1:1 Partnering

11:50 AM - 12:20 PM 1:1 Partnering


img

Jon Kaiser

President & CEO
K-PAX Pharmaceuticals
img

Adi Frish

SVP Business Development & Licensing
RedHill Biopharma
img

Steven Gelone

Chief Scientific Officer & Head, Business Development
Nabriva Therapeutics

1:1 Partnering

12:20 PM - 1:05 PM 1:1 Partnering

1:05 PM - 2:05 PM Luncheon

2:05 PM - 2:20 PM Biotech Spotlights

Volker Schellenberger, President & CEO, AMUNIX

img

Volker Schellenberger

President & CEO
AMUNIX
Constructing a compelling pitch deck
Keys to moving the dialogue forward
Providing substantive evidence for opportunities

img

Kia Motesharei

VP, Global Head of Business Development, Neurology & Immunology Global Busi
EMD Serono
img

Robert Bagdorf

Vice President of Worldwide Business Development
Pfizer Inc.
img

Monica Viziano

Senior Director, Alliance Management
Gilead
img

Michael Bayewitch

Senior Director, Global S&E, Biologics
Teva Pharmaceuticals
img

Andrew Collard

Engagement Manager
Back Bay Life Science Advisors

1:1 Partnering

2:20 PM - 2:50 PM 1:1 Partnering

With a few companies leading the space, are there opportunities for others?
What are the more mature opportunities for therapy and new technology?
What are the outcomes to expect in the coming year?

img

Greg Fond

Director, External Innovation
Sanofi
img

Peter Nell

VP, Head Strategy & Business Development
Casebia Therapeutics
img

Hemmie Chang

Chair, Licensing & Strategic Alliances Practice Group
Foley Hoag

1:1 Partnering

2:50 PM - 3:20 PM 1:1 Partnering

General Session

3:20 PM - 3:50 PM Afternoon Refreshment Break

1:1 Partnering

3:20 PM - 3:50 PM 1:1 Partnering


img

Todd Haim

Program Director, Small Business Innovation Research (SBIR) Development Center
National Cancer Institute (NCI)
img

Anthony Artuso

Chief Business Officer
Synthetic Genomics
img

Upendra Marathi, PhD, MBA

President & CEO
7 Hills Pharma
img

Kate Rittenhouse-Olson

Founder, President and CSO
For-Robin, Inc

James Egan

President & CEO
Targagenix

1:1 Partnering

3:50 PM - 4:55 PM 1:1 Partnering

Current increased spinout interest from large and small pharma
What distinguishes deals that succeed from those that don’t?
How to incentivize investors, licensors, and employees for buy-in?


Moderated by Back Bay Life Science Advisors

img

Alex Rabiee

Director, Business Development
Amgen
img

Christoph Pittius

SVP, Research Business Development
City of Hope
img

Michael Johnson

VP, Business Development
Eli Lilly
img

Sanjay Mistry

Head of External Value Creation, Janssen
Pharmaceutical Companies of Johnson & Johnson
img

Chris Leo

SVP
Back Bay Life Science Advisors

1:1 Partnering

4:55 PM - 5:25 PM 1:1 Partnering

5:25 PM - 6:25 PM Sunset Serenade

6:25 PM - 6:25 PM End of Day One